As the industry leader in conducting human viral challenge studies, hVIVO have developed a large Virobase, of clinical data paired with virological data, host genetics and immunology combined with an extensive biorepository of blood and respiratory samples.

hVIVO has been studying influenza for over 20 years,conducting influenza human challenge studies with our flu disease models for more than 15 years. We have delivered numerous flu challenge studies for a range of industry, governmental and academic partners.

As the global leader in Human Challenge Trials, hVIVO performed the World’s first COVID-19 human challenge trial in 2021. hVIVO has since developed and can offer Wuhan, Delta and Omicron strains of SARS-CoV-2 for Human Challenge Modelling.

hVIVO has an approved and well characterised rhinovirus (HRV-16) that has been used to safely infect individuals in a large number of challenge studies carried out at the main hVIVO containment unit in London.

hVIVO is developing further capability and capacity in its unique Human Challenge facilities to assist in the advancement of novel antimalarial drug and vaccine candidates and is now able to offer a Direct Venous Inoculation (DVI), Controlled Human Malaria Infection (CHMI) model for estimations of efficacy.

hVIVO Challenge Models in Early Respiratory Clinical Development. hVIVO can help with respiratory human challenge in both asthma and chronic obstructive pulmonary disease (COPD)

hLAB’s capabilities for custom assay Development, Validation and tech Transfer to FDA, EMA and ICH guidelines according to GCLP ensuring optimised readouts for assays.

Working with global biologistic partners, hLab can provide all your sample collection kit needs to support your field trial studies.

hLAB provides a broad portfolio of serological and infectivity assays for a range of target pathogens . All our assays are optimised for both data integrity and throughput.

hLab offers full molecular services for quantitative viral load assessments, qualitative diagnostic and respiratory virus panel testing as well as bespoke assay development (e.g. SNP allelic PCR development).

hLab offers compound efficacy assessment services to support Discovery and Pre-clinical compound efficacy for anti-viral compounds; post challenge or vaccination assessment of generation of genetic variants and shifts in compound efficacy

hLAB offers vast and complex customized solutions for biomarker analysis through the development and validation of laboratory assays that allow the quantification and characterization of immune responses in clinical trials.